Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

20171,400 citationsJournal Articlebronze Open Access

Authors

Kenneth G. Saag · University of Alabama at Birmingham

Jeffrey Petersen · Amgen (United States)

Maria Luisa Brandi · University of Florence

Andrew C. Karaplis · McGill University

Mattias Lorentzon · Sahlgrenska University Hospital

Thierry Thomas · Université Claude Bernard Lyon 1

Judy Maddox

Abstract

In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).

Topics & Keywords

Bone health and treatments Bone health and osteoporosis research Bone and Joint Diseases

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 15, pp. 1417-1427

DOI: 10.1056/nejmoa1708322

Field-Weighted Citation Impact: 48.71